It's not necessarily true that you can cross Eli Lilly off the list of potential BP suitors just because they are filing their own EUA. If leronlimab proves to be effective for the s/c population, there's a ton of money to be made, and I think every BP will be in play because they'd rather have a sure thing than a maybe.